NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer

Phase 1

Withdrawn

Conditions: Fallopian Tube Serous Neoplasm
Adult Solid Neoplasm
Ovarian Serous Adenocarcinoma
Ovarian Serous Tumor
Primary Peritoneal Serous Adenocarcinoma
Progesterone Receptor Negative
Recurrent Breast Carcinoma
Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma

Interventions: Drug: Hsp90 Inhibitor AT13387
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Talazoparib

First Posted Date: 2015-12-11

Last Posted Date: 2016-07-26

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT02627430

A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

Phase 2

Recruiting

Conditions: Melanoma

Interventions: Biological: young TIL
Drug: Aldesleukin
Drug: Pembrolizumab
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2015-12-03

Last Posted Date: 2025-03-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 170

Registration Number: NCT02621021

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer

Recruiting

Conditions: Breast Carcinoma

Interventions: Other: Laboratory Biomarker Analysis

First Posted Date: 2015-11-20

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 162

Registration Number: NCT02610426

Locations: 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer

Recruiting

Conditions: Breast Carcinoma

Interventions: Other: Laboratory Biomarker Analysis

First Posted Date: 2015-11-20

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 354

Registration Number: NCT02610413

Locations: 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer

Recruiting

Conditions: Breast Carcinoma
Neuropathy

Interventions: Other: Laboratory Biomarker Analysis

First Posted Date: 2015-11-20

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 575

Registration Number: NCT02610439

Locations: 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma

Phase 1

Terminated

Conditions: High Grade Sarcoma
Recurrent Malignant Peripheral Nerve Sheath Tumor
Metastatic Undifferentiated Pleomorphic Sarcoma
Stage III Uterine Corpus Leiomyosarcoma AJCC v8
Metastatic Leiomyosarcoma
Recurrent Synovial Sarcoma
Recurrent Undifferentiated Pleomorphic Sarcoma
Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8
Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8
Metastatic Malignant Peripheral Nerve Sheath Tumor

Interventions: Drug: Pazopanib
Drug: Sapanisertib
Drug: Pazopanib Hydrochloride

First Posted Date: 2015-11-10

Last Posted Date: 2022-08-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 151

Registration Number: NCT02601209

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
Rocky Mountain Cancer Centers - Pueblo, Pueblo, Colorado, United States

and more 455 locations

Gut Microbiota in People With Hepatocellular Carcinoma (HCC)

Withdrawn

Conditions: Hepatocellular Carcinoma
Liver Cancer
Liver Neoplasm
Liver Cell Caricinoma

First Posted Date: 2015-11-09

Last Posted Date: 2018-09-20

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT02599909

Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer

Phase 2

Completed

Conditions: Stage 0 Breast Cancer AJCC v6 and v7
Stage IA Breast Cancer AJCC v7
Stage IB Breast Cancer AJCC v7
Stage II Breast Cancer AJCC v6 and v7
Stage IIA Breast Cancer AJCC v6 and v7
Stage I Breast Cancer AJCC v7
Stage IIB Breast Cancer AJCC v6 and v7

Interventions: Drug: Exemestane
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Other: Quality-of-Life Assessment
Other: Placebo Administration
Procedure: Therapeutic Conventional Surgery
Other: Questionnaire Administration

First Posted Date: 2015-11-06

Last Posted Date: 2023-08-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 180

Registration Number: NCT02598557

Locations: 🇮🇹
European Institute of Oncology, Milano, Italy
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇮🇹
Galliera Hospital, Genoa, Italy

and more 2 locations

Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

Phase 2

Completed

Conditions: Metastatic Breast Carcinoma
Metastatic Malignant Neoplasm in the Brain
Metastatic BRCA Hereditary Breast Carcinoma
Metastatic Triple-Negative Breast Carcinoma
Recurrent Breast Carcinoma
Stage IV Breast Cancer AJCC v6 and v7

Interventions: Drug: Cisplatin
Other: Laboratory Biomarker Analysis
Other: Placebo Administration
Drug: Veliparib

First Posted Date: 2015-11-04

Last Posted Date: 2025-05-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 344

Registration Number: NCT02595905

Locations: 🇺🇸
Mountain Blue Cancer Care Center, Golden, Colorado, United States
🇺🇸
UCHealth University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸
Boulder Community Hospital, Boulder, Colorado, United States

and more 803 locations

Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery

Phase 1

Terminated

Conditions: Metastatic Renal Cell Carcinoma
Stage III Renal Cell Cancer AJCC v7
Stage I Renal Cell Cancer AJCC v6 and v7
Stage IV Renal Cell Cancer AJCC v7
Clear Cell Renal Cell Carcinoma
Stage II Renal Cell Cancer AJCC v7

Interventions: Procedure: Metastasectomy
Procedure: Nephrectomy
Biological: Nivolumab

First Posted Date: 2015-11-04

Last Posted Date: 2020-10-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 19

Registration Number: NCT02595918

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy